Sabby Management’s Acadia Pharmaceuticals ACAD Stock Holding History

Sabby Management’s Portfolio ACAD Stock Details ACAD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-99,921	Closed	-$4.12M	–	107
2020 Q3	$4.12M	Buy	+99,921	New	+$4.31M	0.62%	29
2016 Q2	–	Sell	-46,258	Closed	-$1.55M	–	288
2016 Q1	$1.29M	Sell	46,258 -67,580	-59%	-$1.47M	0.06%	138
2015 Q4	$4.06M	Buy	+113,838	New	+$4.01M	0.22%	73
2015 Q1	–	Sell	-864,437	Closed	-$27.4M	–	286
2014 Q4	$27.4M	Buy	+864,437	New	+$24.5M	0.87%	18
2014 Q3	–	Sell	-589,264	Closed	-$13.3M	–	257
2014 Q2	$13.3M	Buy	589,264 +126,118	+27%	+$2.63M	0.57%	32
2014 Q1	$11.3M	Sell	463,146 -93,867	-17%	-$2.37M	0.63%	37
2013 Q4	$13.9M	Buy	557,013 +130,413	+31%	+$3.08M	0.89%	28
2013 Q3	$11.7M	Sell	426,600 -377,655	-47%	-$7.89M	0.76%	35
2013 Q2	$14.6M	Buy	+804,255	New	+$11.1M	0.97%	26

Other funds holding ACAD

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

FAM

Fred Alger Management New York $30B AUM 76.99% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Sabby Management's ACAD Position: Q4 2020 in Review

Sabby Management sold out of Acadia Pharmaceuticals (ACAD) in Q4 2020, closing a stake of 99,921 shares — an estimated $4.12M sold.

Sabby Management first reported a position in ACAD in Q2 2013 and held it in 9 quarters. The position peaked at $27.4M in Q4 2014. 308 funds tracked by Wall St. Rank hold ACAD as of Q4 2020.

Sabby Management reported no remaining Acadia Pharmaceuticals position as of Q4 2020 after selling out during the quarter.
Sabby Management sold 99,921 Acadia Pharmaceuticals shares in Q4 2020, an estimated $4.12M.
Sabby Management first reported a position in Acadia Pharmaceuticals in Q2 2013 and held it in 9 quarters.
Sabby Management's Acadia Pharmaceuticals position peaked at $27.4M in Q4 2014.
308 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q4 2020.

Based on Sabby Management's 13F filing for Q4 2020, filed 16 Feb 2021.